Patents Represented by Attorney, Agent or Law Firm Elizabeth A. Hanley
  • Patent number: 6833365
    Abstract: Methods and compositions for treating Cryptosporidium parvum related disorders in a mammal are discussed. Several novel tetracycline compounds useful for treating Cryptosporidium parvum related disorders are also included.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: December 21, 2004
    Assignee: Trustees of Tufts College
    Inventors: Stuart B. Levy, Mark L. Nelson
  • Patent number: 6830898
    Abstract: The present invention features methods for the identification of compounds and compositions useful as antibiotics and antibacterial agents. In particular, the invention features methods for the identification of modulators of a previously unidentified target protein, termed CoaX. High-throughput assay systems are featured as well as assay kits for the identification of CoaX modulators. Also featured are coaX nucleic acid molecules and purified CoaX proteins, as well as recombinant vectors and microorganisms including the gene, coaX.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: December 14, 2004
    Assignee: OmniGene Bioproducts, Inc.
    Inventors: R. Rogers Yocum, Thomas A. Patterson
  • Patent number: 6831165
    Abstract: Isolated nucleic acid molecules, designated HA nucleic acid molecules, which encode novel HA proteins from Corynebacterium glutamicum are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing HA nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated HA proteins, mutated HA proteins, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from C. glutamicum based on genetic engineering of HA genes in this organism.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: December 14, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Markus Pompejus, Burkhard Kröger, Hartwig Schröder, Oskar Zelder, Gregor Haberhauer
  • Patent number: 6822084
    Abstract: Isolated nucleic acid molecules, designated SRT nucleic acid molecules, which encode novel SRT proteins from Corynebacterium glutamicum are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SRT nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated SRT proteins, mutated SRT proteins, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from C. glutamicum based on genetic engineering of SRT genes in this organism.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: November 23, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Markus Pompejus, Burkhard Kroger, Hartwig Schröder, Oskar Zelder, Gregor Haberhauer, Heung-Shick Lee, Hyung-Joon Kim
  • Patent number: 6818635
    Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: November 16, 2004
    Assignees: Paratek Pharmaceuticals, Inc., Trustees of Tufts College
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Beena Bhatia, David Messersmith
  • Patent number: 6818634
    Abstract: Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: November 16, 2004
    Assignees: Paratek Pharmaceuticals, Inc., Trustees of Tufts College
    Inventors: Mark L. Nelson, Stuart B. Levy, Roger Frechette, Todd E. Bowser, Mohamed Y. Ismail
  • Patent number: 6808683
    Abstract: A droplet dispensing system for forming and dispensing droplets of a liquid sample is provided. The droplet dispensing system is fabricated on the tip of a dispensing pin. The tip of the dispensing pin includes a droplet ejection nozzle, a filling channel, a chamber and an actuator for ejecting droplets on demand. The system further includes a holder for mounting the dispensing pin. The holder also contains a control circuit for activating the actuator.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: October 26, 2004
    Assignee: Cytonome, Inc.
    Inventor: John Gilbert
  • Patent number: 6808075
    Abstract: A method and apparatus for sorting particles moving through a closed channel system of capillary size comprises a bubble valve for selectively generating a pressure pulse to separate a particle having a predetermined characteristic from a stream of particles. The particle sorting system may further include a buffer for absorbing the pressure pulse. The particle sorting system may include a plurality of closely coupled sorting modules which are combined to further increase the sorting rate. The particle sorting system may comprise a multi-stage sorting device for serially sorting streams of particles, in order to decrease the error rate.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: October 26, 2004
    Assignee: Cytonome, Inc.
    Inventors: Sebastian Böhm, John R. Gilbert, Manish Deshpande
  • Patent number: 6780987
    Abstract: The invention provides isolated nucleic acids molecules, designated &bgr;CAP73 nucleic acid molecules, which encode a novel actin binding protein. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing &bgr;CAP73 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a &bgr;CAP73 gene has been introduced or disrupted. The invention still further provides isolated &bgr;CAP73 proteins, fusion proteins, mutant proteins, antigenic peptides and anti-&bgr;CAP73 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: August 24, 2004
    Assignee: Trustees of the Tufts College
    Inventors: Ira Herman, Alice Y. Welch
  • Patent number: 6777224
    Abstract: The present invention provides a method for enzymatically producing optically active mandelic acid derivatives. An optically active mandelic acid derivative (shown as Formula II) is produced by reacting a culture or cell body of a microorganism, or processed products thereof, with a phenylglyoxylic acid derivative, and then recovering the obtained optically active mandelic acid derivative, wherein the microorganism has the ability to stereo-selectively reduce the phenylglyoxylic acid derivative. An optically active mandelic acid obtained according to the present invention is useful as an intermediate for the synthesis of pharmaceuticals and agricultural chemicals.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: August 17, 2004
    Assignee: Daicel Chemical Industries, Ltd.
    Inventors: Kazuya Mitsuhashi, Hiroaki Yamamoto
  • Patent number: 6756404
    Abstract: Autoinducer compounds which enhance gene expression in a wide variety of microorganisms, therapeutic compositions and therapeutic methods wherein gene expression within microorganisms is regulated are disclosed.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: June 29, 2004
    Assignee: The Research & Development Institute, Inc.
    Inventor: Tom Livinghouse
  • Patent number: 6756365
    Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: June 29, 2004
    Assignee: Trustees of Tufts College
    Inventor: Stuart B. Levy
  • Patent number: 6723321
    Abstract: Provided are compositions and methods useful for modulating the activity of autoinducer synthase catalysts. A method for identifing modulators of the autoinducer synthesis reaction is also provided. Such modulators are useful for controlling bacterial growth and can be used for therapeutic treatment of bacterial infections particularly in immunocompromised subjects. They are also useful in treating disease states associated with autoinducer synthesis and biofilm development.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: April 20, 2004
    Assignees: The Board of Trustees of the University of Illinois, The University of Iowa Research Foundation
    Inventors: E. Peter Greenberg, John E. Cronan, Jr., Bryce V. Plapp, Matthew R. Parsek
  • Patent number: 6720188
    Abstract: Methods and kits for determine arginine compounds are discussed. The methods and kits of the invention can be used for the diagnosis of arginine compound associated disorders.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: April 13, 2004
    Assignees: FAL Diagnostics
    Inventors: Rima Kaddurah-Daouk, Thomas W. Bell, Alisher B. Khasanov
  • Patent number: 6706764
    Abstract: The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases.
    Type: Grant
    Filed: May 7, 1997
    Date of Patent: March 16, 2004
    Assignees: Avicena Group, Inc., The General Hospital Corporation
    Inventors: Rima Kaddurah-Daouk, Ghaleb Daouk, M. Flint Beal
  • Patent number: 6696561
    Abstract: Isolated nucleic acid molecules, designated MCT nucleic acid molecules, which encode novel MCT proteins from Corynebacterium glutamicum are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MCT nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated MCT proteins, mutated MCT proteins, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from C. glutamicum based on genetic engineering of MCT genes in this organism.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: February 24, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Markus Pompejus, Burkhard Kröger, Hartwig Schröder, Oskar Zelder, Gregor Haberhauer
  • Patent number: 6683068
    Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: January 27, 2004
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tad Warchol, Paul Sheahan
  • Patent number: 6677133
    Abstract: The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity of drugs are provided. Pharmaceutical composition comprising an inhibitor of an AcrAB-like efflux pump and an antimicrobial agent are also provided.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: January 13, 2004
    Assignee: Trustees of Tufts College
    Inventors: Margaret Oethinger, Stuart B. Levy
  • Patent number: 6670399
    Abstract: The invention provides methods of inhibiting cerebral amyloid angiopathy. The invention further provides methods of treating a disease state characterized by cerebral amyloid angiopathy in a subject with an A&bgr;40 inhibitor having the structure: Q-[—SO3−X+]n or Q-[—OSO3−X+]n wherein Q is a carrier group; X+ is a cationic group; and n is one.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: December 30, 2003
    Assignee: Neurochem (International) Limited
    Inventors: Allan M. Green, Francine Gervais
  • Patent number: 6660734
    Abstract: The invention relates to novel oxazinones designed to bind to the penicillin receptor, methods of synthesizing the compounds, and the use of the compounds as antibacterial agents. The compounds have the general formula (I) Preferably the compounds have a carboxyethyl or a substituted carboxymethyl substituent at the 2-position and a hydroxyl group at the 5-position and have a molecular shape suitable for binding to and reacting with the active site of a pencillin-recognizing enzyme. The compounds are synthesized by condensing a carboxyl-protected N-hydroxy amino acid with a 3-hydroxyprotected-4-bromobutanoic acid to form a a doubly protected N-hydroxy N-acylamino acid, which is cyclized with an organic base to yield a: doubly protected 1,2-oxazin-3-one. The protecting groups are then removed to provide an antibacterial agent.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: December 9, 2003
    Assignee: Simon Fraser University
    Inventors: Saul Wolfe, Christiana Akuche, Stephen Ro